Trials / Not Yet Recruiting
Not Yet RecruitingNCT07532252
Daridorexant for Alcohol Use Disorder
A Double-Blind Randomized Controlled Trial of Daridorexant for Alcohol Use Disorder
- Status
- Not Yet Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 150 (estimated)
- Sponsor
- Johns Hopkins University · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study will test whether the dual orexin receptor antagonist (DORA) daridorexant reduces alcohol craving and use and improves total sleep time among patients with co-occurring alcohol use disorder and sleep disturbance. The study will assess the role of the orexin system in modulating alcohol craving and use in a real-world treatment setting.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Daridorexant 50 mg | Daridorexant 50 mg (Orally administered) |
| OTHER | Placebo | Placebo (Oral) |
Timeline
- Start date
- 2027-01-01
- Primary completion
- 2030-08-01
- Completion
- 2031-02-01
- First posted
- 2026-04-15
- Last updated
- 2026-04-15
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT07532252. Inclusion in this directory is not an endorsement.